<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Mult Scler</journal-id><journal-id journal-id-type="iso-abbrev">Mult Scler</journal-id><journal-id journal-id-type="publisher-id">MSJ</journal-id><journal-id journal-id-type="hwp">spmsj</journal-id><journal-title-group><journal-title>Multiple Sclerosis (Houndmills, Basingstoke, England)</journal-title></journal-title-group><issn pub-type="ppub">1352-4585</issn><issn pub-type="epub">1477-0970</issn><publisher><publisher-name>SAGE Publications</publisher-name><publisher-loc>Sage UK: London, England</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40317176</article-id><article-id pub-id-type="pmc">PMC12092934</article-id>
<article-id pub-id-type="doi">10.1177/13524585251338755</article-id><article-id pub-id-type="publisher-id">10.1177_13524585251338755</article-id><article-categories><subj-group subj-group-type="heading"><subject>Controversies in Multiple Sclerosis</subject></subj-group></article-categories><title-group><article-title>Treating comorbidities in MS is disease modifying: Commentary</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3437-812X</contrib-id><name><surname>Palladino</surname><given-names>Raffaele</given-names></name><xref rid="corresp1-13524585251338755" ref-type="corresp"/><aff id="aff1-13524585251338755">Department of Public Health, University &#x02018;Federico II&#x02019; of Naples, Naples, Italy</aff><aff id="aff2-13524585251338755">Department of Primary Care and Public Health, Imperial College of London, London, UK</aff><aff id="aff3-13524585251338755">Interdepartmental Research Center on Management and Innovation in Healthcare, University &#x02018;Federico II&#x02019; of Naples, Naples, Italy</aff></contrib></contrib-group><author-notes><corresp id="corresp1-13524585251338755">R Palladino Department of Public Health, University &#x02018;Federico II&#x02019; of Naples, via Sergio Pansini 5, Naples 80131, Italy. <email>raffaele.palladino@unina.it</email></corresp></author-notes><pub-date pub-type="epub"><day>3</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="ppub"><month>5</month><year>2025</year></pub-date><volume>31</volume><issue>6</issue><fpage>639</fpage><lpage>641</lpage><permissions><copyright-statement>&#x000a9; The Author(s), 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder content-type="sage">SAGE Publications</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the Creative Commons Attribution 4.0 License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (<ext-link ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p></license></permissions><custom-meta-group><custom-meta><meta-name>typesetter</meta-name><meta-value>ts1</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>People with multiple sclerosis (PwMS) exhibit a higher prevalence of comorbidities, particularly cardiovascular, psychiatric, and autoimmune disorders, as compared with the general population.<sup><xref rid="bibr1-13524585251338755" ref-type="bibr">1</xref><xref rid="bibr2-13524585251338755" ref-type="bibr"/>&#x02013;<xref rid="bibr3-13524585251338755" ref-type="bibr">3</xref></sup> These comorbid conditions are frequently undertreated and have been linked to increased relapse rates, accelerated disability progression, diminished health-related quality of life, and heightened mortality.<sup><xref rid="bibr1-13524585251338755" ref-type="bibr">1</xref>,<xref rid="bibr2-13524585251338755" ref-type="bibr">2</xref>,<xref rid="bibr4-13524585251338755" ref-type="bibr">4</xref>,<xref rid="bibr5-13524585251338755" ref-type="bibr">5</xref></sup> Given this substantial impact, an important question arises: could effective comorbidity management, including risk factor control, exert disease-modifying effects in MS? This pivotal issue is explored in depth in the Controversy section of this edition of the <italic toggle="yes">Multiple Sclerosis Journal</italic>.</p><p>Lorefice and Zivadinov argue that the current MS treatment paradigm, which primarily focuses on immunosuppression, fails to address the significant role of comorbidities in disease progression. Cardiovascular, metabolic, psychiatric, and autoimmune conditions exacerbate neurodegeneration through systemic inflammation, oxidative stress, and endothelial dysfunction.<sup><xref rid="bibr6-13524585251338755" ref-type="bibr">6</xref>,<xref rid="bibr7-13524585251338755" ref-type="bibr">7</xref></sup> Despite evidence linking hypertension, dyslipidemia, and diabetes to accelerated MS progression,<sup>
<xref rid="bibr7-13524585251338755" ref-type="bibr">7</xref>
</sup> these conditions remain separate from disease-modifying strategies. When selecting the appropriate disease-modifying treatments (DMTs), MS neurologists should consider that some exhibit cardiovascular benefits,<sup>
<xref rid="bibr7-13524585251338755" ref-type="bibr">7</xref>
</sup> but others may negatively impact metabolic health,<sup>
<xref rid="bibr8-13524585251338755" ref-type="bibr">8</xref>
</sup> highlighting the need for integrated management. Furthermore, psychiatric and autoimmune comorbidities also influence disease outcomes,<sup>
<xref rid="bibr7-13524585251338755" ref-type="bibr">7</xref>
</sup> yet their treatment remains largely adjunctive rather than central to MS care. Beyond pharmacological interventions, optimizing vascular health, cognitive reserve, and brain resilience is crucial for mitigating disability accumulation. The commentary calls for a fundamental shift in MS treatment, advocating for comorbidity-targeted interventions as a core component of disease modification, rather than mere supportive care.</p><p>In the other commentary, Lorscheider acknowledges the importance of comorbidity management in PwMS but challenges its classification as disease-modifying. It argues that DMTs, by definition, must alter disease progression through direct effects on pathophysiology, a criterion that comorbidity-targeted interventions do not currently meet. While hypertension, hyperlipidemia, and psychiatric disorders are linked to worse MS outcomes,<sup>
<xref rid="bibr7-13524585251338755" ref-type="bibr">7</xref>
</sup> existing evidence largely stems from observational studies, making causal inferences unreliable. The MS-STAT2 trial of simvastatin in secondary progressive MS, which failed to slow disability progression, exemplifies the complexity of these associations.<sup>
<xref rid="bibr9-13524585251338755" ref-type="bibr">9</xref>
</sup> Similarly, while some MS therapies improve coexisting autoimmune conditions, others, such as tumor necrosis factor (TNF) inhibitors, effective therapeutic option in rheumatoid arthritis, psoriasis, and inflammatory bowel disease can worsen MS, highlighting the need for caution.<sup>
<xref rid="bibr10-13524585251338755" ref-type="bibr">10</xref>
</sup> Given the limited evidence for direct neuroprotective effects, optimizing comorbidity treatment should be a component of holistic MS care but not be equated with disease modification. The primary focus should remain on halting disability progression through targeted MS-specific therapies.</p><p>In summary, there is broad consensus on the critical importance of comorbidity management in PwMS, which extends beyond the selection of appropriate DMTs and might necessitate the involvement of multiple specialists. While the MS specialist remains central to patient care, an integrated care model, incorporating a multidisciplinary team to support MS management, should be prioritized. However, implementing such a paradigm shift presents significant challenges in terms of economic, human, and financial resources. To optimize treatment strategies and establish clear priorities for effective intervention, high-quality data are needed to guide evidence-based decision-making.</p></body><back><fn-group><fn fn-type="other"><p><bold>Data Availability Statement:</bold> Data sharing not applicable to this article as no data sets were generated or analysed during this study.</p></fn><fn fn-type="COI-statement"><p>The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: R.P. has received support from the UK MS Society (Award 146). In the last 3 years, R.P. has taken part in advisory boards/consultancy for MSD, Sanofi, and BMS.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding:</bold> The author(s) received no financial support for the research, authorship, and/or publication of this article.</p></fn><fn fn-type="other"><p><bold>ORCID iD:</bold> Raffaele Palladino <inline-graphic xlink:href="10.1177_13524585251338755-img1.jpg"/>
<ext-link xlink:href="https://orcid.org/0000-0002-3437-812X" ext-link-type="uri">https://orcid.org/0000-0002-3437-812X</ext-link></p></fn></fn-group><ref-list><title>References</title><ref id="bibr1-13524585251338755"><label>1</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Palladino</surname><given-names>R</given-names></name>
<name><surname>Marrie</surname><given-names>RA</given-names></name>
<name><surname>Majeed</surname><given-names>A</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Evaluating the risk of macrovascular events and mortality among people with multiple sclerosis in England</article-title>. <source>JAMA Neurol</source>
<year>2020</year>; <volume>77</volume>(<issue>7</issue>): <fpage>820</fpage>&#x02013;<lpage>828</lpage>.<pub-id pub-id-type="pmid">32364569</pub-id>
</mixed-citation></ref><ref id="bibr2-13524585251338755"><label>2</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Marrie</surname><given-names>RA</given-names></name>
<name><surname>Kosowan</surname><given-names>L</given-names></name>
<name><surname>Singer</surname><given-names>A</given-names></name>
</person-group>. <article-title>Management of diabetes and hypertension in people with multiple sclerosis</article-title>. <source>Mult Scler Relat Disord</source>
<year>2020</year>; <volume>40</volume>: <fpage>101987</fpage>.<pub-id pub-id-type="pmid">32062442</pub-id>
</mixed-citation></ref><ref id="bibr3-13524585251338755"><label>3</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Marrie</surname><given-names>RA</given-names></name>
<name><surname>Cohen</surname><given-names>J</given-names></name>
<name><surname>Stuve</surname><given-names>O</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: Overview</article-title>. <source>Mult Scler</source>
<year>2015</year>; <volume>21</volume>(<issue>3</issue>): <fpage>263</fpage>&#x02013;<lpage>281</lpage>.<pub-id pub-id-type="pmid">25623244</pub-id>
</mixed-citation></ref><ref id="bibr4-13524585251338755"><label>4</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Marrie</surname><given-names>RA</given-names></name>
<name><surname>Fisk</surname><given-names>J</given-names></name>
<name><surname>Tremlett</surname><given-names>H</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Differing trends in the incidence of vascular comorbidity in MS and the general population</article-title>. <source>Neurol Clin Pract</source>
<year>2016</year>; <volume>6</volume>(<issue>2</issue>): <fpage>120</fpage>&#x02013;<lpage>128</lpage>.<pub-id pub-id-type="pmid">27104065</pub-id>
</mixed-citation></ref><ref id="bibr5-13524585251338755"><label>5</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Conway</surname><given-names>DS</given-names></name>
<name><surname>Thompson</surname><given-names>NR</given-names></name>
<name><surname>Cohen</surname><given-names>JA</given-names></name>
</person-group>. <article-title>Influence of hypertension, diabetes, hyperlipidemia, and obstructive lung disease on multiple sclerosis disease course</article-title>. <source>Mult Scler</source>
<year>2017</year>; <volume>23</volume>(<issue>2</issue>): <fpage>277</fpage>&#x02013;<lpage>285</lpage>.<pub-id pub-id-type="pmid">27230791</pub-id>
</mixed-citation></ref><ref id="bibr6-13524585251338755"><label>6</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Jakimovski</surname><given-names>D</given-names></name>
<name><surname>Topolski</surname><given-names>M</given-names></name>
<name><surname>Genovese</surname><given-names>AV</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Vascular aspects of multiple sclerosis: Emphasis on perfusion and cardiovascular comorbidities</article-title>. <source>Expert Rev Neurother</source>
<year>2019</year>; <volume>19</volume>(<issue>5</issue>): <fpage>445</fpage>&#x02013;<lpage>458</lpage>.<pub-id pub-id-type="pmid">31003583</pub-id>
</mixed-citation></ref><ref id="bibr7-13524585251338755"><label>7</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Marrie</surname><given-names>RA</given-names></name>
<name><surname>Fisk</surname><given-names>JD</given-names></name>
<name><surname>Fitzgerald</surname><given-names>K</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Etiology, effects and management of comorbidities in multiple sclerosis: Recent advances</article-title>. <source>Front Immunol</source>
<year>2023</year>; <volume>14</volume>: <fpage>1197195</fpage>.<pub-id pub-id-type="pmid">37325663</pub-id>
</mixed-citation></ref><ref id="bibr8-13524585251338755"><label>8</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Zhao</surname><given-names>Z</given-names></name>
<name><surname>Lv</surname><given-names>Y</given-names></name>
<name><surname>Gu</surname><given-names>ZC</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Risk for cardiovascular adverse events associated with sphingosine-1-phosphate receptor modulators in patients with multiple sclerosis: Insights from a pooled analysis of 15 randomised controlled trials</article-title>. <source>Front Immunol</source>
<year>2021</year>; <volume>12</volume>: <fpage>795574</fpage>.<pub-id pub-id-type="pmid">34950154</pub-id>
</mixed-citation></ref><ref id="bibr9-13524585251338755"><label>9</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Chataway</surname><given-names>J</given-names></name>
<name><surname>Williams</surname><given-names>T</given-names></name>
<name><surname>Blackstone</surname><given-names>J</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis (MS-STAT2 trial): A multicentre, randomised placebo-controlled, double-blind, phase 3 clinical trial</article-title>. <source>Multiple Sclerosis Journal</source>
<year>2024</year>; <volume>30</volume>(<issue>suppl 3</issue>): <fpage>1138</fpage>&#x02013;<lpage>1147</lpage>.</mixed-citation></ref><ref id="bibr10-13524585251338755"><label>10</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Konen</surname><given-names>FF</given-names></name>
<name><surname>M&#x000f6;hn</surname><given-names>N</given-names></name>
<name><surname>Witte</surname><given-names>T</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Treatment of autoimmunity: The impact of disease-modifying therapies in multiple sclerosis and comorbid autoimmune disorders</article-title>. <source>Autoimmun Rev</source>
<year>2023</year>; <volume>22</volume>(<issue>5</issue>): <fpage>103312</fpage>.<pub-id pub-id-type="pmid">36924922</pub-id>
</mixed-citation></ref></ref-list></back></article>